{ CD95 (also called Fas and APO-1) is a prototypical death receptor that regulates tissue homeostasis mainly in the immune system through the induction of apoptosis [1] [2] [3] . During cancer progression CD95 is frequently downregulated or cells are rendered apoptosis resistant 4, 5 , raising the possibility that loss of CD95 is part of a mechanism for tumour evasion. However, complete loss of CD95 is rarely seen in human cancers 4 and many cancer cells express large quantities of CD95 and are highly sensitive to CD95-mediated apoptosis in vitro. Furthermore, cancer patients frequently have elevated levels of the physiological ligand for CD95, CD95L 6 . These data raise the possibility that CD95 could actually promote the growth of tumours through its non-apoptotic activities 7 . Here we show that cancer cells in general, regardless of their CD95 apoptosis sensitivity, depend on constitutive activity of CD95, stimulated by cancer-produced CD95L, for optimal growth. Consistently, loss of CD95 in mouse models of ovarian cancer and liver cancer reduces cancer incidence as well as the size of the tumours. The tumorigenic activity of CD95 is mediated by a pathway involving JNK and Jun. These results demonstrate that CD95 has a growth-promoting role during tumorigenesis and indicate that efforts to inhibit its activity rather than to enhance it should be considered during cancer therapy.
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To test the function of endogenous CD95 in tumour cells, expression of CD95 was reduced in various human cancer cell lines using CD95-specific short hairpin (sh)RNA lentiviruses ( Supplementary  Fig. 1 ). Infection of the CD95 high-expressing ovarian cancer cell line HeyA8, which is sensitive to CD95-mediated apoptosis in vitro, with a lentiviral shRNA against CD95, CD95shRNA6 (R6), substantially reduced CD95 protein and surface expression resulting in loss of CD95 apoptosis sensitivity (Fig. 1a) . Abrogation of CD95 expression also resulted in substantial growth reduction. This was confirmed with another CD95-targeting shRNA (R4) ( Supplementary Fig. 2 ) and in another ovarian cancer cell line, SKOV3.ip1, which expresses very low amounts of CD95 and is completely resistant to CD95L-induced apoptosis (Fig. 1b and data not shown) . Reconstitution of the SKOV3.ip1 CD95 knockdown cells with a short interfering (si)RNA-resistant version of CD95 to endogenous levels restored the growth of SKOV3.ip1 cells (Supplementary Fig. 3 ). A growthinhibiting effect of reducing CD95 expression was also found in cell lines derived from colon (HCT116), renal (CAKI-1), breast (MCF7) and liver (HepG2) cancers (Fig. 1c-f ). Knocking down CD95 in MCF7 cells with the R6 virus resulted, 6 days after infection, in growth arrest (data not shown). However, 26 days after infection cells expressing intermediate CD95 levels grew out, albeit with reduced growth as compared to vector-control infected cells (Fig. 1e) . Neither MCF7 nor CAKI-1 cells benefited from overexpressing CD95 ( Supplementary  Fig. 4 ), suggesting that cancer cells, regardless of the absolute level of CD95 expression, maintain expression of CD95 at a level sufficient to promote optimal growth. This is consistent with our previous report that in 22 tumour cell lines stimulation of CD95 did not result in increased proliferation 6 . However, incubating cells with the neutralizing CD95L monoclonal antibody (mAb) NOK-1 reduced cell growth ( Supplementary Fig. 5a ), indicating that the small amount of CD95L produced by tumour cells (Supplementary Fig. 5b ) contributes to their growth. To test this assumption directly, we used lentivirus-based shRNAs specific for CD95L that knocked down CD95L in a murine cell line expressing full-length human CD95L ( Supplementary Fig. 5c ). We monitored growth of HepG2 cells infected with each of three independent CD95L-specific shRNA viruses, all of which caused a reduction of CD95L expression (Fig. 1g) . Paralleling the efficiency of the knockdown, the viruses caused different degrees of growth inhibition ranging from a reduction in growth (L2) to a complete loss of growth (L1) (Fig. 1h) . Knocking down CD95L using an siRNA SmartPool ( Supplementary  Fig. 5c ) also resulted in profound growth inhibition of HepG2 cells ( Supplementary Fig. 5d ). Finally, knocking down CD95L also reduced the growth of all other cancer cell lines, indicating that CD95L is essential for the growth of many tumour cells (Fig. 1i) . The knockdown of CD95 in HepG2 only caused a moderate reduction in growth, possibly because this knockdown may not have been efficient enough to cause a more pronounced effect. Given the small amount of CD95L expressed in tumour cells, reducing its expression is more likely to cause severe effects by falling below a threshold of minimal expression. This interpretation is consistent with a recent analysis that determined that the threshold for CD95 to signal apoptosis versus non-apoptotic signalling is 1,000 times higher 8 . Our data indicate that almost undetectable amounts of CD95 and CD95L are sufficient and in some cases required to promote growth of tumour cells.
CD95 is highly expressed in epithelial ovarian cancer but these cancer cells acquire resistance to CD95-mediated apoptosis 9 . Large quantities of CD95L are found in patient ascites 10, 11 and patient serum 12 . As a first step towards understanding the role of CD95 in ovarian cancer in vivo we used an intraperitoneal xenograft model of metastatic ovarian cancer 13 . Nude mice injected with SKOV3.ip1 cells infected with either the R6 (Fig. 2a) or the R4 (Fig. 2b ) virus had about a 50% reduction in tumour mass, number of metastases and ascites formation. To test whether CD95-dependent tumour growth was driven by CD95L in vivo, SKOV3.ip1 cells were grown for one week in nude mice and then treated with either a neutralizing anti-CD95L mAb specific for mouse CD95L (MFL3) or for human CD95L (NOK-1). Tumour growth was attenuated only in mice injected with the human CD95L-specific antibody (Fig. 2d) , suggesting that it is predominantly the CD95L produced by the human cancer cells (Fig. 2d, inset ) rather than CD95L produced by the microenvironment in the mouse host that drives CD95-mediated tumour growth.
To test whether the growth-promoting role of CD95 could also be found in actual ovarian cancer, we used a primary ovarian cancer cell line (MONTY-1 14 ) at an early passage number. CD95 was knocked down in MONTY-1 cells (again resulting in reduced proliferation; Supplementary Fig. 6 ) after which these cells were injected into nude mice. Similar to findings with SKOV3.ip1 cells, MONTY-1 cells with reduced CD95 expression were completely resistant to CD95-mediated or CD95shRNA6 (R6) as determined by western blot analysis. A similar effect was also found with a CD95-expressing variant of the neuroblastoma cell line NB4 (not shown). Apoptosis sensitivity of HeyA8 vec and R6 cells by leucine zipper-tagged (Lz)CD95L treatment was determined by quantifying DNA fragmentation (a). OD, optical density. g, HepG2 cells were stably infected with three different CD95L-specific shRNA lentiviruses (L1, L2 and L4) and CD95L mRNA was quantified using real-time PCR. h, Growth of cells in g over 5 days. i, Growth of different cell lines infected with the L4 virus. Proliferation of cells was examined by SRB assay (a-f, h and i). *P , 0.05, **P , 0.01, ***P , 0.001. Values in graphs represent mean 6 s.d. from three independent experiments. d, day.
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LETTERS apoptosis and showed reduced intra-abdominal tumour load (Fig. 2e) . Also similar to findings with SKOV3.ip1 cells (Fig. 2c ) this result could, at least in part, be explained by a reduced proliferation rate (reduced Ki67 staining) and reduced vascularization (reduced CD31 staining). The tumours showed an increase in TUNEL (TdT-mediated dUTP nick end labelling) staining, indicating that the inhibition of the growth-promoting CD95 receptor caused cancer cells to die (Fig. 2f) .
Similar to other subtypes of epithelial ovarian cancers 9 , the endometrioid subtype expresses CD95 (Fig. 3a) , suggesting that in ovarian cancer CD95 could promote tumorigenesis. To test this we used a genetic model of epithelial endometrioid ovarian cancer based on the expression of activated mutant Kras and deletion of Pten 15 . For these studies we generated Kras/Pten mutant mice carrying loxP sites in the CD95 gene 16 ( Supplementary Fig. 7 ). Cancer formation was initiated by injecting adenovirus Cre into the right ovarian bursa of the mice. Eight weeks after injection nine out of twelve mice expressing wildtype CD95 had formed an ovarian cancer in the injected ovary with no cancer in the uninjected control ovary, whereas only one of the eleven mice with knocked-out CD95 had an early cancer (Fig. 3b-d) . Although wild type mice started to die 8-9 weeks after Cre injection in this model, only one of four mice lacking CD95 in the ovaries had an early cancer after 14 weeks. Immunohistochemistry confirmed that CD95 was highly expressed in the cancerous ovaries of wild-type mice and efficiently knocked out in the Cre-injected ovaries of mice carrying the floxed CD95 alleles (Fig. 3d) . Polymerase chain reaction (PCR) analysis to detect deleted Pten confirmed that the Cre recombinase was equally active in cells of either genotype ( Supplementary  Fig. 7c ). The data indicate that CD95 has a role in the tumorigenesis of ovarian cancer.
Liver is the tissue with the highest constitutive CD95 expression. It has previously been shown that mice expressing an apoptosissignalling-deficient mutant of CD95 have a defect in liver regeneration after partial hepatectomy 17 , raising the possibility that CD95 is involved in liver regeneration. To determine if it is the CD95 expressed on hepatocytes that drives their proliferation, we generated hepatocyte-specific CD95-knockout mice by crossing CD95 loxP mice with mice expressing the Cre recombinase under control of the liverspecific albumin promoter (Alb-Cre mice) (Supplementary Fig. 8 ).
These mutant mice were then subjected to two-thirds partial hepatectomy. Proliferation of hepatocytes was severely impaired 48 h after the procedure in the absence of CD95 on hepatocytes (Fig. 4a, b) , confirming that CD95 expression on hepatocytes is required for their proliferation. This raised the possibility that CD95 might also promote liver cancer.
Prolonged damage to the liver accompanied by compensatory hepatocyte proliferation can promote hepatocarcinogenesis 18 , a process that can be recreated in a mouse model of diethylnitrosamine (DEN)-induced hepatocellular carcinoma. As compared to wild-type mice, mice lacking expression of CD95 in the liver showed a clear reduction in incidence and size of hepatocellular carcinoma eight months after a single injection of DEN (Fig. 4c) . These data indicate that CD95 contributes to hepatocarcinogenesis. Ki67 staining in the tumours of CD95-deficient livers was reduced (Fig. 4d, e) , consistent with a contribution of CD95 to the growth of liver cancer. Because it was previously shown that expression of Cre recombinase can affect the apoptosis-sensitivity of certain tissues 19 , we confirmed our data in Cre-expressing mice of a different genotype (Supplementary Fig. 9 ). DEN has been described as inducing liver damage through a mechanism that involves reactive oxygen species 18 . Consistently, reduction of hepatocellular carcinoma in mice lacking CD95 expression in the liver could not be ascribed to a decrease in DEN-induced damage because injection of DEN into 15-day-old or adult wild-type or CD95-knockout mice did not induce significantly increased apoptosis and caused a similar activation of JNK ( Supplementary Fig. 10 ). However, the proliferative response (Ki67 staining) of hepatocytes in DEN-injected mice was strongly reduced in CD95-deficient livers ( Supplementary Fig. 10a ). Our data support a role of CD95 in liver regeneration that translates into an increase in hepatocarcinogenesis in a chemically induced model of liver cancer.
JNK1-deficient mice have a reduced ability to recover from partial hepatectomy and are less susceptible to DEN-induced liver cancer 20, 21 . Recently this link between JNK1 activation and hepatocellular carcinoma was confirmed in humans by two independent studies. Hepatocellular carcinoma patients showed increased activation of JNK1 in cancer cells when compared to adjacent non-cancerous tissue 20, 22 . Consistent with a function of JNK in proliferation of tumour cells we found that treatment of tumour cell lines with the JNK inhibitor SP600125 completely inhibited their growth (Supplementary Fig. 11a and Supplementary Results). Notably, hepatocytes from CD95-deficient mice showed reduced phosphorylation of JNK and the JNK substrate Jun (Fig. 4f) , suggesting that loss of CD95 reduced the basal activity of JNK, resulting in loss of proliferative capacity. To test whether stimulation of CD95 in the liver causes activation of JNK, we injected wild-type mice with the agonistic anti-CD95 mAb, Jo2. Injection of Jo2 caused a massive increase in the phosphorylation of JNK and Jun both in mice that possessed an intact liver (these mice died when injected with Jo2) and in mice subjected to partial hepatectomy (known to protect mice from liver death 17 as evidenced by a lack of caspase-3 cleavage, TUNEL staining and an increase in the liver enzyme alanine transaminase (ALT)) ( Fig. 4g and Supplementary Fig. 12a) . A clear increase in intracellular phospho-Jun staining of hepatocytes ( Supplementary Fig. 12b ) indicated that JNK was activated in hepatocytes in response to CD95 stimulation in mice protected from apoptosis by partial hepatectomy. The link between CD95 and the JNK pathway was also found in endometrioid tumours from Kras/Pten mutant mice. Tumour tissue taken from cancerous ovaries expressing CD95 stained strongly for both CD95 and nuclear phospho-Jun, whereas tumour tissue from mice deficient for CD95 expression in the ovaries not only lacked expression of CD95 but was also devoid of phospho-Jun staining (Fig. 4h) .
In aggregate, the data suggest that cancer cells and the regenerating liver require a basal activity of CD95 to activate JNK, resulting in phosphorylation of Jun and driving proliferation. To identify further downstream effectors in this pathway we isolated RNA from HeyA8 cells with knocked-down CD95 (two independent shRNAs were used), from HepG2 cells with knocked-down CD95 and from CD95-deficient livers, and compared gene expression profiles to the corresponding parental/wild-type cells. Interestingly, among all three systems, there were only two genes that were downregulated to a greater extent than CD95 itself-early growth 1 (Egr1) and the AP1 component Fos (Supplementary Fig. 13a-c) . Both genes are downstream of JNK and are essential growth-promoting transcription factors 23, 24 . Consistent with their function, both Egr1 and Fos were strongly upregulated in the liver of Jo2-injected, partially hepatectomized mice (Supplementary Fig. 13d ) and their expression was strongly reduced in CD95-deficient ovarian cancer ( Supplementary  Fig. 13e ). Our data indicate that the CD95/CD95L system, rather than being tumour suppressive, drives cancer growth-joining the ranks of TNFR1 and TNF-a in stimulating tumour growth. In line with our results, studies suggest that CD95 activates neuronal stem cells 25 and acts as a tumour promoter for glioblastoma by activating Src kinases 26 . Furthermore, it was recently shown that mice that only express soluble CD95L suffer from large histiocytic sarcomas in the liver 27 probably due to a lack of apoptosis induction and a tumorigenic activity of CD95L. Our data indicate that CD95 exerts a growth-promoting activity mainly through a pathway involving JNK, Jun, Erg1 and Fos, and that tumour cells are stimulated by their own CD95L. The data provide an explanation for the uncertainty about the role of CD95 expression in many tissues and in most human cancers without signs of apoptosis in vivo, and suggest that efforts to inhibit rather than to promote CD95 activity should be considered during cancer therapy.
METHODS SUMMARY
Endometrioid ovarian cancer induction. The method of ovarian cancer induction using LSL-Kras
WT/WT and LSL-Kras
Pten loxP/loxP CD95 loxP/loxP female mice was described previously 28 . Briefly, mice were sedated, the right ovary was exposed and the ovarian bursa was injected with Cre (2.5 3 10 7 plaque-forming units) (University of Iowa Gene Transfer Vector Core). The left ovary was not injected and served as an internal control. Mice were evaluated weekly for palpable tumour and all were killed 8 or 14 weeks after the injection of the virus. At the time of death the primary tumour was excised, weighed, measured and the number of metastatic nodules and volume of ascites were recorded. All tissues were fixed in 10% formalin, embedded in paraffin, and stained with haematoxylin and eosin. Partial hepatectomy. Two-thirds partial hepatectomy was performed as previously described 29, 30 . In brief, mice were anaesthetized with ketamine (100 mg kg
21
) and xylazine (10 mg kg 21 ) intraperitoneally (i.p.), the liver was exposed through a midline incision, and the right and left lobes were sequentially ligated with a silk 4-0 suture and resected. BrdU solution (50 mg kg 21 in PBS) was injected i.p. 2 h before analysis. DNA synthesis was measured by immunohistochemical staining of paraffin liver sections with anti-BrdU antibody. The percentage of BrdU-positive hepatocyte nuclei among total hepatocyte nuclei was calculated using the Cellular Image Analysis System (ACIS, Clarient). Liver cancer induction. Fifteen-day-old CD95 loxP/loxP (wild-type) and CD95 loxP/loxP Alb-Cre (CD95-knockout) male mice were injected with a single dose of DEN (25 mg g 21 body weight, i.p.). Eight months later, all mice were killed and livers were excised. Parameters of total liver weight, number of liver surface nodules and maximum nodule diameters were recorded.
In Fig. 1f of the original Letter, an incorrect actin blot was published: see the corrected panel in Fig. 1 of this Corrigendum. Also, in the original Supplementary Fig. 12c , some of the western blot data were either misinterpreted or raw data could not be located. We have now repeated the entire experiment: see Supplementary Information to this Corrigendum for the corrected Supplementary Fig. 12c . Although there are differences between the different experiments, the increase in phosphorylation of JNK and Jun was reproducible, confirming that stimulation of CD95 causes activation of JNK. All the conclusions of the original Letter are intact except for the data for the original 
